NorthWest Biotherapeutics Inc (NWBO)

[Rkmatters]

He likes to give all credit to RT/TMZ for most of 100 patients who haven’t seen a PFS event. This is impossible. The skeptics conveniently forgets that only 8% of the patients had good prognostic factors. Only 65% of the 108 had potential for RT/TMZ pseudoprogression. And simply having pseudoprogression doesn’t mean patients go on to non-event. But he sure would like to get folks to believe that survival in this trial isn’t impressive the same we he argued that pseudoprogression would cause PFS events.

“Unknown factors: sub-group with extended survival
Approximately 30% of the ITT population (n?=?100) showed particularly extended survival, with a KM derived mOS estimate of 40.5 months. This is not fully explained by known prognostic factors, as only some of these patients had positive prognostic factors: only 29% were younger than 50 years of age, 65.9% had methylated MGMT, 71% had a complete resection, and only 8% of these patients had all three positive prognostic factors. These patients will be the subject of extensive further analyses and research.” -—— JoTM May 2018 paper